Healthcare / BiotechnologyLSE
$0.65
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-971500.00 · quality 53.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
25/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$5M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-163.5%
↓Gross Margin
100.0%
↑Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2024 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-13341.1%
FCF / Net income
0.92x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $7282.0 · net income $-1.1M · FCF $-971500.0
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $7282.00 | $7282.00 | $1953.00 | — | — |
| Net Income | $-1.1M | $-1.1M | $-1.3M | $-1.0M | $-1.5M |
| EBITDA | $-1.2M | $-1.2M | $-1.3M | $-1.2M | $-1.8M |
| EPS | -0.00 | -0.00 | -0.01 | -0.01 | -0.01 |
| Gross Margin | 100.0% | 100.0% | 100.0% | — | — |
| Operating Margin | -15928.2% | -15928.2% | -68377.8% | — | — |
| Net Margin | -14537.5% | -14537.5% | -64993.9% | — | — |
| Balance Sheet | |||||
| Current Ratio | 23.55 | 23.55 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-971500.00 | $-971500.00 | $-1.2M | $-828263.00 | $-1.8M |
| Returns | |||||
| ROE | -163.5% | -163.5% | -112.6% | -49.3% | -72.5% |
| Valuation | |||||
| P/B | 342.12 | 342.12 | 280.02 | 165.16 | 400.91 |
| Growth & Yield | |||||
| Revenue Growth | 272.9% | 272.9% | — | — | — |
| EPS Growth | 40.4% | 40.4% | 5.5% | 35.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+36.8%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.01 → -0.00
Residual
+36.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.